Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

bout Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 study. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BOCA RATON, Fla. , Dec. 19, 2014 /PRNewswire/ ... entered into a multi-product agreement with MSN Laboratories Pvt. ... Breckenridge and MSN expect to commercialize several new ANDAs. ... manufacture, and supply the products exclusively to Breckenridge for ... the products under its label.  Breckenridge and MSN have ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... 14, 2011  Heska Corporation (NASDAQ: HSKA ; ... and specialty products to veterinarians, announced today the intent ... expertise in blood-related disorders.  The parties are to explore ... cell-based therapeutics, for use in the veterinary market.      ...
... Group, Inc. (OTCMARKETS: UYMG) "UNITY" (or the "Company"), and its ... it has sold its initial PZ Uno Tablet press to ... the company is not able to disclose the name of ... tablet press would be used for a research and development ...
Cached Medicine Technology:Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 2Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 3Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000 2
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... 20, 2014 DePuy Pinnacle hip ... version of the artificial hip system was defectively ... federal courts, Bernstein Liebhard LLP reports. According to ... Superior Court on December 2nd, counsel in 10 ... of plaintiffs on November 19, 2014, with depositions ...
(Date:12/20/2014)... VogueQueen.com, a leading wedding dress wholesaler and retailer, has ... 2015. Great discounts are now offered on all of ... a discount, up to 80% off, when they place ... 2015. , VogueQueen.com has recently released its new arrival ... Many customers worldwide like VogueQueen’s special designs which feature ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP ... suggests that children treated with the medication may ... to breast development and lactation. The study, which ... children and adolescents who began treatment with risperidone, ...
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... study from the University of Michigan Comprehensive Cancer Center ... prognosis and are 35 percent more likely to doe ... cancer and found that blacks with advanced cancer had ... it. ,Results of the study appear in the ...
... Heart, Lung and Blood Institute (NHLBI) Working Group finds ... treating depression// in their patients, they are more likely ... The report is published in "Annals of Behavioral Medicine" ... to 20 percent of patients with heart disease meet ...
... this week’s British Medical Journal, the doctors must contemplate ... Richard Lehman writes that this matter in spite of ... national level in the profession. ,Over the ... centralising services, and many local campaigns over individual threatened ...
... protein molecules called enzymes catalyze specific biochemical reactions in ... or structure play a major role in enzyme catalysis. ... energy landscape" of the enzyme that directs it to ... of the energetic barriers to these catalytic changes. The ...
... the August issue of the American Journal of Roentgenology ... tomography (MDCT) in diagnosing// the spread of breast cancer. ... 69 patients to examine the efficiency of both tests. ... 44 cases, while MDCT correctly diagnosed 27. "MRI revealed ...
... issued a warning that drugs used to treat attention ... psychiatric side-effects that could manifest as agitation and even ... rare incidences of side-effects, that all drugs used to ... warnings, by the beginning of December. , ,Canadian ...
Cached Medicine News:Health News:Bladder Cancer Has Worse Outcomes In Blacks 2Health News:Cardiologists Ignoring Treatment Of Depression 2Health News:Deliberation on hospital closures 2Health News:"Dynamic Energy Landscape" of enzyme in Catalysis 2
Inquire...
... Subcutaneous Lead System Model 6996 ... the use of the Medtronic ... SQ design and implant technique ... and easy procedure, and high ...
... Spiral HP catheters feature 20 bipolar-spaced ... the highest degree of mapping resolution ... mapping via a 20-pole catheter enables ... potentials than with 10-pole catheter systems. ...
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee...
Medicine Products: